ISDA

Entry Detail

PDB ID:

3S9I

Keywords:

Title:

Crystal structure of Mycobacterium tuberculosis malate synthase in complex with 2-4-dioxo-4-phenylbutanoic acid inhibitor

Biological Source:

Source Organism:

Mycobacterium tuberculosis

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2011-06-01

Release Date:

2012-11-07

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.90 Å

R-Value Free:

0.20

R-Value Work:

0.16

R-Value Observed:

0.17

Space Group:

P 43 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Malate synthase G
Mutations:c619A
Chain IDs:A
Chain Length:741
Number of Molecules:1
Biological Source:Mycobacterium tuberculosis

UniProt ID:P9WK17 Pfam ID:PF20656, PF20658, PF01274, PF20659 EC:2.3.3.9

Ligand Molecules

XI7

Primary Citation

Structure-guided discovery of phenyl-diketo acids as potent inhibitors of M. tuberculosis malate synthase.

Krieger, I.V, Freundlich, J.S, Gawandi, V.B, Roberts, J.P, Gawandi, V.B, Sun, Q, Owen, J.L, Fraile, M.T, Huss, S.I, Lavandera, J.L, Ioerger, T.R, Sacchettini, J.C.Show

Chem.Biol. 19 1556 1567 (2012)

PMID: 23261599 DOI: 10.1016/j.chembiol.2012.09.018

Abstact

The glyoxylate shunt plays an important role in fatty acid metabolism and has been shown to be critical to survival of several pathogens involved in chronic infections. For Mycobacterium tuberculosis (Mtb), a strain with a defective glyoxylate shunt was previously shown to be unable to establish infection in a mouse model. We report the development of phenyl-diketo acid (PDKA) inhibitors of malate synthase (GlcB), one of two glyoxylate shunt enzymes, using structure-based methods. PDKA inhibitors were active against Mtb grown on acetate, and overexpression of GlcB ameliorated this inhibition. Crystal structures of complexes of GlcB with PDKA inhibitors guided optimization of potency. A selected PDKA compound demonstrated efficacy in a mouse model of tuberculosis. The discovery of these PDKA derivatives provides chemical validation of GlcB as an attractive target for tuberculosis therapeutics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures